Global Gene Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Indication Type;
Cancer, Cardiovascular Indication, Infectious diseases indication, Genetic diseases indication, Neurological diseases indication, and Others.By Technology;
Adeno Virus Vector, Adeno-associated Virus Vector, Lentiviral Vector, Retroviral Vector, Herpes Virus Vector, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Gene Therapy Market (USD Million), 2021 - 2031
In the year 2023, the Global Gene Therapy Market was valued at USD 4,320.27 million. The size of this market is expected to increase to USD 21,782.36 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 26.0%.
Gene therapy holds immense potential to address unmet medical needs and transform the treatment paradigm by targeting the underlying cause of diseases at the genetic level. By delivering therapeutic genes or gene-modifying agents into target cells, gene therapy offers the possibility of correcting genetic defects, restoring normal cellular functions, and even eradicating diseases altogether. This paradigm shift from conventional symptomatic treatments to curative therapies represents a fundamental breakthrough in medicine, with profound implications for patients, healthcare providers, and society as a whole.
The market for gene therapy is propelled by several key factors driving its rapid expansion. Technological advancements, particularly in viral and non-viral vector systems for gene delivery, have significantly enhanced the safety, efficacy, and scalability of gene therapy approaches. Moreover, regulatory agencies worldwide have shown increasing support and willingness to expedite the development and approval of gene therapy products, recognizing their transformative potential in addressing unmet medical needs.
The growing investment from biopharmaceutical companies, academic institutions, and government initiatives has catalyzed research and development efforts in gene therapy, leading to a robust pipeline of novel therapeutics targeting a diverse array of diseases. Additionally, the rising prevalence of genetic disorders, cancer, and chronic diseases, coupled with the aging population and increasing healthcare expenditure, underscores the urgent need for innovative treatment modalities like gene therapy.
Global Gene Therapy Market Recent Developments
-
In January 2024, Biogen and Ginkgo Bioworks announced that they have completed the gene therapy collaboration involving AAV based vectors. This is expected to fuel the demand for gene therapies in coming years.
-
In December 2023, Swiss Agency for Therapeutic Products granted approval to Libmeldy for treatment of early-onset metachromatic leukodystrophy.
-
In May 2023, Krystal Biotech was granted approval for VYJUVEK gene therapy for Dystrophic Epidermolysis Bullosa treatment
-
In June 2023, the U.S. FDA granted approval to Sarepta for ELEVIDYS gene therapy to treat DMD in children of age 4-5 years
-
In January 2023, Voyager Therapeutics and Neurocrine Biosciences entered into a strategic collaboration for commercialization & development of Voyager’s GBA1 program and other next-generation gene therapies for neurological diseases
-
In January 2023, Spark Therapeutics and Neurochase established a strategic collaboration to develop Neurochase’s unique delivery technology for use with selected gene treatments for rare disorders in the CNS. In this agreement, Neurochase will contribute its extensive knowledge in direct drug delivery technology to Spark’s premier AAV platform.
-
In January 2022, 64x Bio, a U.S.-based biotech company, raised USD 55.0 million in funding to advance its gene therapy manufacturing platform. This initiative was expected to expand the company’s VectorSelect platform.
Segment Analysis
Indication Type segmentation categorizes the market based on the therapeutic areas targeted by gene therapy interventions. This includes indications such as cancer, genetic disorders, neurological disorders, cardiovascular diseases, infectious diseases, and others. Each indication presents unique challenges and opportunities for gene therapy development, with ongoing clinical trials and commercialization efforts aimed at addressing unmet medical needs across diverse patient populations.
Technology segmentation delves into the various approaches and techniques employed in gene therapy interventions. This encompasses viral vectors, non-viral vectors, gene editing technologies (such as CRISPR-Cas9), and others. Viral vectors, including adenoviruses, lentiviruses, and adeno-associated viruses (AAVs), are commonly used delivery vehicles for introducing therapeutic genes into target cells, while non-viral vectors offer alternative strategies with potential advantages in terms of safety and scalability. Gene editing technologies enable precise modification of genetic sequences, holding promise for treating inherited disorders and manipulating disease pathways.
Geographical segmentation provides insights into regional dynamics and market trends across key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global gene therapy market, driven by strong research infrastructure, supportive regulatory environment, and substantial investment in biotechnology and pharmaceutical sectors. Europe follows closely, with a growing emphasis on personalized medicine and increasing adoption of innovative therapies. Asia-Pacific emerges as a promising market, fueled by rising healthcare expenditure, expanding biotech industry, and growing awareness of genetic diseases.
Global Gene Therapy Segment Analysis
In this report, the Global Gene Therapy Market has been segmented by Indication Type, Technology and Geography.
Global Gene Therapy Market, Segmentation by Indication Type
The Global Gene Therapy Market has been segmented by Indication Type into Cancer, Cardiovascular Indication, Infectious diseases indication, Genetic diseases indication, Neurological diseases indication and Others.
Cancer remains one of the primary indications for gene therapy, fueled by the urgent need for effective treatments against various types of malignancies. Gene therapies targeting cancer aim to deliver therapeutic genes or modify existing ones to suppress tumor growth, enhance immune responses, or induce apoptosis in cancer cells. These innovative approaches hold promise for personalized and targeted cancer treatments, offering new hope to patients with previously untreatable or refractory cancers.
Cardiovascular indications represent another significant segment within the gene therapy market. With cardiovascular diseases remaining a leading cause of morbidity and mortality worldwide, gene therapy offers potential solutions for conditions such as heart failure, ischemic heart disease, and genetic disorders affecting cardiac function. Gene-based interventions aim to restore normal cardiac function, enhance vascular regeneration, or modulate risk factors associated with cardiovascular diseases, thereby addressing unmet medical needs and improving patient outcomes.
Infectious diseases indication is a rapidly evolving segment in the gene therapy landscape, particularly in the context of emerging infectious threats and antimicrobial resistance. Gene-based strategies for infectious diseases encompass various approaches, including gene editing to confer resistance to pathogens, enhancing host immune responses against infections, and delivering therapeutic genes to target infected cells or pathogens directly. These innovative interventions hold promise for combating infectious diseases, including viral infections, bacterial infections, and emerging infectious threats with limited treatment options.
Genetic diseases indication represents a cornerstone of gene therapy development, focusing on inherited genetic disorders caused by mutations in single genes or genetic defects. Gene therapies for genetic diseases aim to correct or replace defective genes, restore normal cellular function, and alleviate disease symptoms or progression. These transformative treatments offer hope to patients with rare genetic disorders, metabolic diseases, and inherited syndromes, providing potentially curative or disease-modifying interventions where conventional treatments are often limited to symptom management.
Neurological diseases indication encompasses a diverse spectrum of disorders affecting the central nervous system, including neurodegenerative diseases, neuromuscular disorders, and neurological genetic disorders. Gene therapy holds immense potential for addressing neurological diseases by delivering therapeutic genes, modulating gene expression, or targeting pathological mechanisms underlying neurodegeneration. These innovative approaches offer new avenues for treating diseases such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and rare neurological disorders with significant unmet medical needs.
Global Gene Therapy Market, Segmentation by Technology
The Global Gene Therapy Market has been segmented by Technology into Adeno Virus Vector, Adeno-associated Virus Vector, Lentiviral Vector, Retroviral Vector, Herpes Virus Vector, and Others.
Among these technologies, Adeno Virus Vector stands out as a prominent player, owing to its high efficiency in delivering genetic material to a wide range of cell types. Adeno-associated Virus Vector, renowned for its low immunogenicity and long-lasting transgene expression, has emerged as a frontrunner, particularly in treating genetic disorders affecting the central nervous system and muscular system. Lentiviral Vector, derived from the human immunodeficiency virus (HIV), offers efficient gene delivery and stable integration into the host genome, making it a valuable tool in both research and clinical applications.
Retroviral Vector, known for its ability to integrate genetic material into the host genome, holds promise in treating genetic disorders and cancer through targeted gene correction and immunotherapy approaches. Herpes Virus Vector, leveraging the natural tropism of herpes simplex virus, exhibits potential in gene delivery to neuronal cells and has shown efficacy in preclinical studies for neurological disorders.
The market includes other vector delivery systems, each with its unique characteristics and applications, contributing to the diversity and versatility of gene therapy approaches. These technologies, collectively driving innovation and therapeutic breakthroughs, have spurred a surge of interest from biopharmaceutical companies, academic research institutions, and regulatory agencies worldwide.
Despite the immense potential of gene therapy, several challenges persist, hindering widespread adoption and commercialization. Issues such as vector immunogenicity, off-target effects, limited payload capacity, and manufacturing scalability pose hurdles in the development and delivery of safe and effective gene therapies. Furthermore, regulatory requirements, reimbursement policies, and ethical considerations surrounding gene editing technologies raise complex questions regarding patient access, affordability, and societal acceptance.
Global Gene Therapy Market, Segmentation by Geography
In this report, the Global Gene Therapy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Gene Therapy Market Share (%), by Geographical Region, 2024
North America remains at the forefront of gene therapy advancements, driven by robust research infrastructure, strong regulatory support, and substantial investment from biotechnology and pharmaceutical companies. The region boasts a mature healthcare system and a high prevalence of genetic disorders, fostering a conducive environment for market growth. Additionally, strategic collaborations between academia, industry, and government entities further accelerate innovation and commercialization efforts.
Europe stands as a prominent market for gene therapy, characterized by a supportive regulatory framework, increasing investment in biotechnology research, and a growing emphasis on personalized medicine. Countries like the UK, Germany, and France are witnessing substantial adoption of gene therapies across various therapeutic areas, propelled by rising awareness among healthcare professionals and patients, along with favorable reimbursement policies.
Asia Pacific emerges as a key growth frontier in the global gene therapy landscape, fueled by a rapidly expanding healthcare sector, rising healthcare expenditure, and a large patient population. Countries like China, Japan, and India are witnessing a surge in clinical trials and investments in gene therapy research and development. Moreover, advancements in biotechnology, government initiatives to promote innovation, and collaborations with international partners contribute to the region's market expansion.
Middle East and Africa present untapped potential for gene therapy adoption, albeit with some challenges related to healthcare infrastructure, regulatory frameworks, and access to advanced therapeutics. Nevertheless, increasing awareness about genetic diseases, improving healthcare infrastructure, and rising investment in healthcare technologies are gradually shaping the region into an emerging market for gene therapy.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Gene Therapy Market. These factors include; Market Drivers, Restraints and Opportunities.
Drivers, Restraints and Opportunitiy Analysis
Drivers:
- Growing Pipeline of Gene Therapy Products
- Clinical Success and Regulatory Approvals
-
Rising Prevalence of Genetic Disorders and Chronic Diseases - One of the primary drivers propelling the adoption of gene therapy is its ability to target genetic abnormalities directly. Traditional treatment modalities often focus on managing symptoms rather than correcting the underlying genetic defects. Gene therapy, however, involves the introduction, modification, or silencing of specific genes to restore normal cellular function or inhibit disease progression. This precision targeting holds immense promise for patients with genetic disorders, providing hope for improved outcomes and enhanced quality of life.
The increasing understanding of the genetic basis of diseases has fueled the development of novel gene therapy strategies. Advances in genomics, molecular biology, and gene editing technologies have led to the identification of potential therapeutic targets and the development of innovative gene delivery systems. Viral vectors, non-viral vectors, and genome editing tools, such as CRISPR-Cas9, enable researchers to design sophisticated gene therapy constructs tailored to individual patient needs.
The growing availability of regulatory approvals for gene therapy products has also accelerated market growth. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established pathways for the expedited review and approval of gene therapy products, particularly those addressing unmet medical needs or targeting rare diseases. These regulatory advancements provide companies with clearer pathways to commercialization and incentivize investment in gene therapy research and development.
The expanding landscape of gene therapy clinical trials reflects increasing industry interest and investment in this field. Pharmaceutical companies, biotechnology firms, and academic institutions are actively pursuing gene therapy programs across a wide range of therapeutic areas. Collaborations and partnerships between industry stakeholders facilitate the sharing of resources, expertise, and infrastructure, driving innovation and accelerating the translation of promising gene therapy candidates from bench to bedside.
Restraints:
- Safety Concerns and Adverse Events
- High Development Costs
-
Limited Clinical Evidence and Market Access - At the heart of this restraint lies the need for robust clinical evidence to demonstrate the safety, efficacy, and long-term outcomes of gene therapy interventions. While early-stage clinical trials have shown promising results, the limited availability of comprehensive data from large-scale, long-term studies poses uncertainties regarding the durability of treatment effects, potential adverse events, and patient outcomes over time. This scarcity of evidence not only hampers the confidence of regulatory agencies in approving gene therapies but also creates challenges in convincing healthcare payers to reimburse these innovative treatments.
The high cost and resource-intensive nature of conducting clinical trials for gene therapy further exacerbate the issue of limited clinical evidence. The complexities involved in recruiting and monitoring patients, ensuring adequate follow-up periods, and addressing ethical considerations contribute to the relatively slow pace of generating conclusive data. As a result, many gene therapy developers struggle to navigate the regulatory pathways and meet the evidentiary standards required for market authorization, delaying the availability of these potentially life-saving treatments to patients in need.
Beyond the realm of clinical evidence, market access presents another formidable barrier to the widespread adoption of gene therapies. Even when regulatory approvals are obtained, securing favorable reimbursement decisions from healthcare payers remains a formidable challenge. The high upfront costs associated with gene therapy treatments, coupled with uncertainties surrounding their long-term value and cost-effectiveness, often deter payers from providing adequate coverage and reimbursement, limiting patient access to these innovative therapies.
The complex pricing dynamics and reimbursement frameworks across different healthcare systems and regions add another layer of complexity to market access efforts. Gene therapy developers must navigate a maze of pricing negotiations, health technology assessments, and value-based reimbursement models to ensure that their products are accessible and affordable to patients while still achieving financial sustainability.
Opportunities:
- Expanded Applications
- Precision Medicine
-
Gene Editing Technologies - One of the primary opportunities presented by gene editing technologies in the global gene therapy market is the potential for personalized medicine. With the ability to precisely edit genetic sequences, researchers and clinicians can tailor therapies to individual patients based on their unique genetic makeup and disease profiles. This level of customization enhances treatment efficacy while minimizing adverse effects, thereby revolutionizing the landscape of healthcare delivery and patient outcomes.
Gene editing technologies offer a versatile platform for the development of novel therapeutic modalities. Beyond traditional gene replacement strategies, these technologies enable a wide range of applications, including gene knockouts, gene silencing, and gene insertion, among others. This versatility allows for the targeting of diverse disease mechanisms and pathways, expanding the scope of gene therapy beyond monogenic disorders to encompass multifactorial diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders.
Gene editing technologies present opportunities for accelerating the drug discovery and development process. By facilitating precise modifications of cellular and animal models, researchers can better elucidate disease mechanisms, identify therapeutic targets, and assess the efficacy and safety of potential interventions. This enables more efficient preclinical screening of candidate therapies, reducing development timelines and costs while increasing the likelihood of successful translation to clinical applications.
Competitive Landscape Analysis
Key players in Global Gene Therapy Market include:
- Gilead Sciences, Inc.
- Novartis
- Amgen Inc.
- Bluebird Bio
- Biogen Inc
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Indication Type
- Market Snapshot, By Technology
- Market Snapshot, By Region
- Global Gene Therapy Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Growing Pipeline of Gene Therapy Products
-
Clinical Success and Regulatory Approvals
-
Rising Prevalence of Genetic Disorders and Chronic Diseases
-
- Restraints
-
Safety Concerns and Adverse Events
-
High Development Costs
-
Limited Clinical Evidence and Market Access
-
- Opportunities
-
Expanded Applications
-
Precision Medicine
-
Gene Editing Technologies
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Gene Therapy Market, By Indication Type, 2021 - 2031 (USD Million)
-
Cancer
-
Cardiovascular Indication
-
Infectious diseases indication
-
Genetic diseases indication
-
Neurological diseases indication
-
Others
-
- Global Gene Therapy Market, By Technology, 2021 - 2031 (USD Million)
-
Adeno Virus Vector
-
Adeno-associated Virus Vector
-
Lentiviral Vector
-
Retroviral Vector
-
Herpes Virus Vector
-
Others
-
- Global Gene Therapy Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Gene Therapy Market, By Indication Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Gilead Sciences, Inc.
- Novartis
- Amgen Inc.
- Bluebird Bio
- Biogen Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market